RH Nanopharmaceuticals
Monmouth Beach, New Jersey, United States
About RH Nanopharmaceuticals
RH/Nanopharma is a pharmaceutical research and development company dedicated to treating, preventing, slowing and reversing inflammatory diseases. Inflammation is at the heart of conditions such as osteoarthritis,type 2 diabetes, acute and chronic pain, traumatic brain injury, Alzheimer’s Disease, Dry Eye Disease (DED), inflammatory bowel disorders such as ulcerative colitis and Crohn’s Disease. RH NANO has reformulated a medication called salsalate which has been used for arthritis and diabetes for over 100 years. RH NANO is proud to be the first pharmaceutical company to successfully produce a nanoparticle of salsalate to be used in all the above mentioned inflammatory disorders. Salsalate in both standard and nanoparticle size is the safest anti-inflammatory/analgesic medicine known to physicians.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Last round: Grant (Sep 2019)
- Website: rhnanopharma.com
- Phone: 908-489-8760
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/rh-nanopharmaceuticals-2554005 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.